PriceKJGordonBABirdSRet al.A review of guidelines for cardiac rehabilitation exercise programs: is there an international consensus?Eur J Prev Cardiol2016; 23: 1715–1733.
PiepoliMFHoesAWAgewallSet al.2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Prev Cardiol2016; 23: NP1–NP96.
4.
Olsen SJS, Schirmer H, Wilsgaard T, et al. Cardiac rehabilitation and symptoms of anxiety and depression after percutaneous coronary intervention. Eur J Prev Cardiol 2018; 25: 1017–1025.
5.
PogosovaNKotsevaKDe BacquerDet al.Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: results from the EUROASPIRE IV survey. A registry from the European Society of Cardiology. Eur J Prev Cardiol2017; 24: 1371–1380.
6.
KotsevaKWoodDde BacquerDet al.EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol2016; 23: 636–648.
7.
KotsevaKDe BacquerDDe BackerGet al.Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. Eur J Prev Cardiol2016; 23: 2007–2018.
8.
Sulo G, Igland J, Vollsett SE, et al. Trends in incident acute myocardial infarction in Norway: an updated analysis through 2014 using national data from CVDNOR projects. Eur J Prev Cardiol 2018; 25: 1031–1039.
9.
ChernomordikFSabbagATzurBet al.Cardiac rehabilitation following an acute coronary syndrome: trends in referral, predictors and mortality outcome in a multicenter national registry between years 2006–2013: report from the Working Group on Cardiac Rehabilitation, the Israeli Heart Society. Eur J Prev Cardiol2017; 24: 123–132.
10.
GlisicMShahzadSTsoliSet al.Association between progestin-only contraceptive use and cardio-metabolic outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol2018; 25: 1042–1052.
11.
RuddoxVSandvenIMunkhaugenJet al.Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol2017; 24: 1555–1566.
12.
EHRA Scientific Committee Task Force. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Eur J Prev Cardiol2017; 24: 4–40.
13.
Casiglia ET, Tikhonoff V, Albertini V, et al. Caffeine intake reduces incident atrial fibrillation at a population level. Eur J Prev Cardiol 2018; 25: 1055–1062.
14.
ClaesJBuysRBudtsWet al.Longer-term effects of home-based exercise interventions on exercise capacity and physical activity in coronary artery disease patients: a systematic review and meta-analysis. Eur J Prev Cardiol2017; 24: 244–256.
15.
HansenDDendalePConinxKet al.The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: a digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology. Eur J Prev Cardiol2017; 24: 1017–1031.
16.
SatoTYoshihisaAKannoYet al.Cardiopulmonary exercise testing as prognostic indicators: comparisons among heart failure patients with reduced, mid-range and preserved ejection fraction. Eur J Prev Cardiol2017; 24: 1979–1987.
17.
Kokkinos P, Kaminsky LA, Arena R, et al. A new generalized cycle ergometry equation for predicting maximal oxygen uptake: the Fitness Registry and the Importance of Exercise National Database (FRIEND). Eur J Prev Cardiol 2018; 25: 1077–1082.
18.
Danchin N, Almahmeed W, Al-Rasadi K, et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol 2018; 25: 1087–1094.
19.
Corra U and Piepoli MF. Secondary prevention: where we are. In: Guazzi M, Lambrinou E and Vrints C (eds) Essentials of secondary prevention. Eur J Prev Cardiol 2017; 24: 14–21.
20.
LeipoldRRaalFIshakJet al.The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: a modelling analysis. Eur J Prev Cardiol2017; 24: 1843–1850.
21.
Buonuomo PS, Macchiaiolo M, Leone G, et al. Treatment of homozygous familial hypercholesterolaemia in paediatric patients: a monocentric experience. Eur J Prev Cardiol 2018; 25: 1098–1105.
22.
EllisKLPangJSchultzCJet al.New data on familial hypercholesterolaemia and acute coronary syndromes: the promise of PCSK9 monoclonal antibodies in the light of recent clinical trials. Eur J Prev Cardiol2017; 24: 1200–1205.
23.
Penaloza-RamosMCJowettSBartonPet al.Costeffectiveness analysis of different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack: economic analysis of the PAST-BP study. Eur J Prev Cardiol2016; 23: 1590–1598.
24.
Penaloza-RamosMCJowettSMantJet al.Costeffectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR). Eur J Prev Cardiol2016; 23: 902–912.
25.
BramlagePSimsHMinguetJet al.The polypill: an effective approach to increasing adherence and reducing cardiovascular event risk. Eur J Prev Cardiol2017; 24: 297–310.
